Learn about our commitment to FGFR-driven diseases
Discover the role of FGFR inhibition
Learn about PROPEL and PROPEL 2
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration To Co-Develop and Commercialize Infigratinib in Oncology
BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
I am an HCP and would like to someone from QED to contact me.
8000 Marina Blvd, Suite 400, Brisbane, CA 94005
For additional information, reach out to firstname.lastname@example.org
By selecting “Proceed” you will leave QEDTx.com and be directed to an external website.